Sorafenib With or Without BIIB022 in Hepatocellular Carcinoma (HCC) This study is currently recruiting participants. Purpose This is a phase 1b/2, open-Label, randomized study of Sorafenib with or without BIIB022 in subjects with advanced hepatocellular carcinoma. Study Type:  Interventional Study Design: Treatment, Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study Official Title: A Phase 1b/2, Open-Label, Randomized Study of Sorafenib With or Without BIIB022 in Subjects With Advanced Hepatocellular Carcinoma Further study details as provided by Biogen Idec: Primary Outcome Measures: Phase 1b: To determine the RP2D of BIIB022 given once every 3 weeks in combination with sorafenib in subjects with advanced HCC. [ Time Frame: 6 months ] [ Designated as safety issue: No ] Phase 2: To compare the time-to-progression (TTP) of BIIB022 in combination with sorafenib with sorafenib monotherapy in subjects with advanced HCC. [ Time Frame: 15 months ] [ Designated as safety issue: No ]   Estimated Enrollment:   172 Study Start Date:   August 2009 Estimated Study Completion Date:   March 2012 Estimated Primary Completion Date:   January 2012 (Final data collection date for primary outcome measure)   Arms Assigned Interventions Sorafenib Monotherapy: Experimental Sorafenib Monotherapy Drug: Sorafenib Standard dosing of Sorafenib Sorafenib with BIIB022: Experimental Sorafenib with BIIB022 Drug: BIIB022 IV Q3W Eligibility Ages Eligible for Study:   18 Years and older Genders Eligible for Study:   Both Accepts Healthy Volunteers:   No Criteria Inclusion Criteria: Age ≥18 years Histologically-confirmed advanced HCC with at least 1 target lesion measurable by modified RECIST. Child-Pugh score A5 or A6. ECOG Performance Status of ≤2.   Exclusion Criteria: Known central nervous system or brain metastases. Prior anti-IGF-1R therapy. Prior systemic therapy for advanced HCC. Prior local therapies are only permitted if subjects have documented disease progression according to modified RECIST. Concurrent anticancer therapy. History of myocardial infarction within 12 months prior to Day 1 or chronic heart failure. Acute hepatitis Fibrolamellar HCC Other protocol-defined inclusion/exclusion criteria may apply Please refer to: www.biogenideconcology.com Please refer to the clinicaltrials.gov website for further details on the study: http://www.clinicaltrial.gov/ct2/show/NCT00956436 To contact Biogen, click here.